Dormir mal no solo pasa factura al estado de ánimo o a la concentración. Cada vez hay más evidencia científica que vincula dormir pocas horas con el aumento de peso y el riesgo de obesidad. En una sociedad que duerme menos que nunca, entender esta relación es clave …
El tétanos es una enfermedad infecciosa poco frecuente en países con alta cobertura vacunal, pero potencialmente mortal si no se trata a tiempo. A pesar de que existe una vacuna eficaz desde hace décadas, cada año se siguen registrando casos en distintas partes del mundo, …
El viaje en el tiempo ha sido durante décadas territorio de la ciencia ficción. Desde Back to the Future hasta Interstellar, pasando por novelas como The Time Machine de H. G. Wells, la posibilidad de desplazarnos hacia el pasado o el futuro ha alimentado nuestra imaginación. Pe …
Las paradojas temporales: ¿qué ocurriría si pudiéramos viajar en el tiempo? Read More »
Rare disease drug developers struggle to survive in a biopharma investment market that prioritizes large patient populations. Initiatives like the Orphan Therapeutics Accelerator are attempting to solve what CEO Craig Martin says is not a science problem, but a math problem.
Cashing In on ‘Creative Fundamentals’ To Fund Rare Disease R&D Read More »
Regulators overseeing rare disease treatments need better tools to weigh competing risks in real time. Sarepta Therapeutics’ Elevidys is a prime example of why.
Opinion: Balancing Safety Access in Rare Disease—Lessons From Sarepta Read More »
LB Pharma needed $350 million to advance a promising schizophrenia candidate at a time when the biotech markets were locked up tight. Fortunately, it wasn’t CEO Heather Turner’s first rodeo.
How LB Rode the Brutal Capital Markets to One of 2025’s Most Successful IPOs Read More »
The Dexcom CEO will lead the lobbying group’s sector representing diabetes tech companies around the world.
AdvaMed names Jake Leach as chair of diabetes sector Read More »
Taking an early proof of concept into preclinical and clinical development is a costly and complex process. But there are strategic ways to streamline the process and reduce risk and costs. In this webinar, you’ll hear directly from Nobel Laureate Sir Michael Houghton and experts from Applied Pharma, who bring decades of real-world success and
Webinar: Lean Derisking: Taking Your Proof of Concept to the Clinic Read More »
The deal, which will take Enhabit private, comes after private equity investments in healthcare reached record highs last year.
Private equity firm to buy home health and hospice provider Enhabit in $1.1B deal Read More »
CEO Scott Whitaker said the medtech lobbying group stands ready to work with President Donald Trump to address trade imbalances by confronting unfair foreign practices in the sector.
AdvaMed urges tailored tariff approach for medtech Read More »
